• 1
    Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol. 1997; 145: 211208.
  • 2
    Kerrigan SA, Turnnir RT, Clement PB, et al. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer. 2002; 94: 378385.
  • 3
    Battifora H, McCaughey WTE. Tumors of the serosal membranes. In: Atlas of tumor pathology. Third series. Fascicle 15. Washington, DC: Armed Forces Institute of Pathology, 1995.
  • 4
    Weiss SW. World Health Organization, International Histological Classification of Tumours. Histological typing of soft tissue tumours. 2nd edition. Berlin: Springer-Verlag, 1994.
  • 5
    Kannerstein M, Churg J. Progress in surgical pathology. Vol II, 1980; 1920.
  • 6
    Johansson L, Linden CJ. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest. 1996; 109: 109114.
  • 7
    Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol. 2004; 17: 476481.
  • 8
    Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol. 1977; 8: 8394.
  • 9
    Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980; 68: 356362.
  • 10
    Sebbag G, Yan H, Shmookler BM, et al. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000; 87: 15871593.
  • 11
    Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999; 6: 790796.
  • 12
    Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol. 2003; 83: 147153.
  • 13
    Jacquet P, Sugarbaker DJ. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15: 4958.
  • 14
    Goldblum J, Hart WR. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol. 1995; 19: 11241137.
  • 15
    Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003; 27: 10311051.
  • 16
    Taub RN, Keohan ML, Chabot JC, Fountain KS, Plitsas M. Peritoneal mesothelioma. Curr Treat Options Oncol. 2000; 1: 303312.
  • 17
    Zellos LS, Sugarbaker DJ. Diffuse malignant mesothelioma of the pleural space and its management. Oncology. 2002; 16: 907925.
  • 18
    van Ruth S, Baas P, Zoetmulder FA. Surgical treatment of malignant pleural mesothelioma: a review. Chest. 2003; 123: 551561.
  • 19
    Waxman A, Goss G, Merriam P, et al. Survival for patients with peritoneal mesothelioma: aggressive multimodality therapy for early stage disease [abstract 2223]. Presented at the American Society of Clinical Oncology Annual Meeting, New Orleans, May 20–23, 2000.
  • 20
    Ramael M, Jacobs W, Weyler J, et al. Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). J Pathol. 1994; 172: 247253.
  • 21
    Beer TW, Carr NJ, Whittaker MA, et al. Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma. Ann Diagn Pathol. 2004; 4: 143148.
  • 22
    Kratzke RA, Otterson GA, Lincoln CE, et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst. 1995; 87: 18701875.
  • 23
    Hirao T, Bueno R, Chen CJ, et al. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis. 2002; 23: 11271130.
  • 24
    Testa JR, Giordano A. SV40 and cell cycle perturbations in malignant mesothelioma. Semin Cancer Biol. 2001; 11: 3138.
  • 25
    Dazzi H, Hasleton PS, Thatcher N, et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer. 1990; 61: 924926.
  • 26
    Robledo R, Mossman B. Cellular and molecular mechanisms of asbestos-induced fibrosis. J Cell Physiol. 1999; 180: 158166.
  • 27
    Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998; 157(5 Pt 1): 16661680.
  • 28
    Janne PA, Taffaro ML, Salgia R, et al. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002; 62: 52425247.
  • 29
    Schwartz GK. Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol. 1996; 23: 316324.
  • 30
    Karakiulakis G, Papanikolaou C, Jankovic SM, et al. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis. 1997; 17: 158168.
  • 31
    Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000; 6: 23492355.
  • 32
    Sato H, Kida Y, Mai M, et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene. 1992; 7: 7783.
  • 33
    Edwards JG, McLaren J, Jones JL, et al. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer. 2003; 88: 15531559.
  • 34
    Liu Z, Klominek J. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax. 2003; 58: 198203.
  • 35
    Lumb PD, Suvarna SK. Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease. Histopathology. 2004; 44: 345352.
  • 36
    Hirano H, Tsuji M, Kizaki T, et al. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study. Med Electron Microsc. 2002; 35: 1623.
  • 37
    Liu Z, Ivanoff A, Klominek J. Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer. 2001; 91: 638643.
  • 38
    Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003; 21: 45604567.